Posted: October 25, 2019
PEARKO Therapeutics Inc. is developing innovative therapies for cardiovascular disease. PEARKO’s most advanced treatment is an enhanced form of a natural
peptide called apelin that controls vascular and heart function. PEARKO’s proprietary apelin analog therapy is designed to help protect the cardiovascular system from conditions where the body may not produce enough apelin, including heart failure and heart attack. PEARKO’s medical innovations, including apelin analogs and other therapies, aim to improve patient quality of life and prolong survival through better treatment and ultimately the prevention of heart and vascular diseases.
• Gavin Oudit, MD, Ph.D,, FRCPC Faculty of Medicine & Dentistry, University of Alberta; founder and chief operating officer, Pearko Therapuetics Inc.
• John Vederas, Ph.D., professor of Chemistry, University of Alberta; co-founder and chief technology officer, Pearko Therapeutics Inc.
The TEC Edmonton Innovation Awards celebrate the success of University of Alberta researchers. In 2019, awards were presented to ten University of Alberta spin-off companies and nine research teams that received a US patent and have an industry partner.